Merck & Co Inc at Evercore ISI HealthCONx Conference Transcript

Nov 30, 2023 / 06:20PM GMT
Umer Raffat - Evercore ISI Institutional Equities, Research Division - Senior MD & Senior Analyst of Equity Research

Listen, thank you guys for being here. Apologies, I'm a couple of minutes behind. Pleasure to have Merck management join us. This is our last fireside of this conference, at least from my end. So really looking forward to it. Peter promised it will be action-packed. And so let's jump right into it.

Questions and Answers:

Umer Raffat - Evercore ISI Institutional Equities, Research Division - Senior MD & Senior Analyst of Equity Research

I think it will be a great idea, maybe let me turn it over to you, Peter and Eliav, to kick things off. Maybe frame for us what's on top in terms of priority list on your mind, and we'll jump right in.

Eliav Barr - Merck & Co., Inc. - Chief Medical Officer & Head of Global Clinical Development of Merck Research Laboratories

Sure. This has been a tremendous year for Merck, and we're looking forward to 2024. The things that are top of mind for us,
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot